Primary Recipient

FRONTIER SCIENCE & TECHNOLOGY RESEARCH FOUNDATION, INC.

Amount

$797,350.00

Award Date

7/16/2009

Administering Agency

Health and Human Services, Department of / National Institutes of Health

CDFA Number

93.701

CDFA Program Title

Trans-NIH Recovery Act Research Support

Description

The E4508 randomized phase II clinical trial will evaluate the combination of chemotherapy with EGFR inhibition, IGF-1R inhibition or both. Although the clinical study accrual rate is estimated at 12 months, there will be an interim toxicity analysis requ

Recipients Connected to Award

Recipient	Role	Amount
REGENTS OF THE UNIVERSITY OF COLORADO, THE	Sub-recipient	$403,691.00
FRONTIER SCIENCE & TECHNOLOGY RESEARCH FOUNDATION, INC.	Primary recipient	$271,085.00
NORTHWESTERN UNIVERSITY	Sub-recipient	$97,762.00
DANA-FARBER CANCER INSTITUTE, INC.	Sub-recipient	$15,265.00
UNIVERSITY OF WISCONSIN SYSTEM	Sub-recipient	$9,547.00